NTLA

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on September 1, 2026, it awarded inducement grants to 41 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points $75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 4:05 p.m. ET.

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.

Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.99 per share a year ago.

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the second quarter ended June 30, 2026.